anti-IL-11, mAb (rec.) (blocking) (X203) (preservative free)

Interleukin-11 (IL-11) is a 19 kDa monomeric protein. IL-11 forms a hexameric signaling complex, which consists of the cytokine, the cognate receptor (IL-11Rα) and the common signaling receptor (GP130) in a 2:2:2 stoichiometry. Interleukin-11 (IL-11) belongs to the IL-6 family of cytokines, which includes IL-6, leukemia inhibitory factor, Oncostatin M, ciliary neurotrophic factor, cardiotrophin-1, cardiotrophin-like cytokine, neuropoietin, IL-27 and IL-31.

Interleukin-11 (IL-11) has diverse biological activities: i) it stimulates the proliferation and differentiation of hematopoietic stem cells and progenitor cells,  enhances the production of megakaryocytes, leading to increased platelet production (thrombopoiesis);  ii)  IL-11 activates fibroblasts and exhibits either a pro-inflammatory or pro-fibrotic phenotype. Recently, IL-11 has been shown to be a key factor in 'inflammaging' (chronic inflammation), one of the hallmarks of aging leading to age-related illnesses, including cardiometabolic, neurodegenerative, musculoskeletal dysfunction and cancer. Inhibition of IL-11 has been shown to increase lifespan and health span in mice. IL-11 influences aging by inducing IL-33 in fibroblasts and NLRP3 in macrophages.

The clone X203 effectively inhibited IL-11-mediated activation of downstream STAT3 phosphorylation and blocks IL-11-dependent gene expression in vitro and in vivo. It neutralizes both human and murine IL-11, demonstrated blockade of IL-11-STAT3 signaling axis, reduced pro-fibrotic transcriptional responses in multiple models, and has been used in preclinical models of renal fibrosis, aging-associated inflammation, and oncogenesis. So, inhibition of IL-11 by X203 is a potential new approach to reduce inflammation during aging and increase human healthspan and lifespan.